About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels. Main lines of research:
The group has participated in different phase II, III and IV clinical trials focused on the study of the immunogenicity, efficacy and safety of several preventive vaccines (e.g. influenza, human papilloma virus, hepatitis B, herpes zoster, respiratory syncytial virus…).
Currently, our group has expanded its line of research on the adjuvanted recombinant Herpes Zoster vaccine testing its safety and immunogenicity in pediatric immunosuppressed patients and adults =50 years of age with a prior episode of Herpes Zoster. Regarding observational studies, the group is leading a population study about the incidence of herpes zoster by risk groups (PI15/02273).
Our team has also started a new line of investigation for a Respiratory Syncytial Virus vaccine in healthy pregnant women.
IP: Xavier Martínez Gómez
IP: Pere Soler Palacín
IP: María Nieves Larrosa Escartin Collaborators: Jose Angel Rodrigo Pendás, Maria Belén Viñado Perez, Mª Carmen Ferrer Barberà, Nuria Fernández Hidalgo, Rosa Alcaraz Peñarrocha, Ma Dolores Rodríguez Pardo, Vanessa Casares Rodríguez, Albert Moreno Mingorance Funding agency: Instituto de Salud Carlos III Funding: 90750 Reference: PI21/01786 Duration: 01/01/2022 - 30/06/2026
The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.
The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
